US4820720A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Transdermal drug composition with dual permeation enhancers
Assignee: Alza Corp
•
Filing: 1988-03-29
•
Granted: 1989-04-11
•
Expires: 2008-03-29
Abstract
Abstract A dosage form that coadministers a drug and two percutaneous absorption enhancers to a defined area of the skin is described. The dosage form comprises a body that contains supplies of drug and enhancers and has a basal surface that contacts the area of skin and transmits the drug and enhancers to the area for absorption thereby.
Inventors
- 👤 Harold F. Sanders
- 👤 Yu-Ling Cheng
- 👤 David J. Enscore
- 👤 Shari B. Libicki
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-28 20:38
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7038; A61K9/7046; A61K9/7053; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/14; A61K9/0012; A61K9/0014; A61K9/7084
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
47 words
A composition of matter for application to a body surface or membrane to deliver a drug at a therapeutically effective rate by permeation through a body surface or membrane comprising, in combination: a dual permeation enhancer comprising glycerol monolaurate and ethanol, and the drug to be delivered.
Claim 2
Dependent Claim
47 words
A composition of matter for application to a body surface or membrane to deliver a drug at a therapeutically effective rate by permeation through a body surface or membrane comprising, in combination: a dual permeation enhancer comprising glycerol monolaurate and ethanol, and the drug to be delivered.
Claim 3
Dependent Claim
19 words
The composition of claim 1 further comprising a carrier having said dual permeation enchancer and said drug dispersed throughout.
Claim 4
Dependent Claim
13 words
The composition of claim 2 wherein said ethanol is separate from said drug.
Claim 5
Dependent Claim
26 words
The composition of claim 3 wherein said ethanol is in a continuous ethanol phase and said glycerol monolaurate and drug are dispersed throughout a polymer matrix.
Claim 6
Dependent Claim
16 words
The composition of claim 4 wherein said continuous ethanol phase is further comprised of glycerol monolaurate.
Claim 7
Dependent Claim
16 words
The composition of claim 2 wherein said glycerol monolaurate and ethanol are separate from said drug.
Claim 8
Dependent Claim
11 words
The composition of claim 2 wherein said body surface is skin.
Claim 9
Dependent Claim
30 words
The composition of claim 1 wherein said drug is selected from the group consisting of calcium channel blockers, estradiol and its esters, ergonovine and ergot alkaloids, opiates and narcotic analgesics.
Claim 10
Dependent Claim
13 words
The composition of claim 8 wherein said drug is a calcium channel blocker.
Claim 11
Dependent Claim
12 words
The composition of claim 9 wherein said calcium channel blocker is nilvadipine.
References Cited (Backward Citations)
DE1001949B
Cited
US3527864A
Cited
US3472931A
Cited
US3598123A
Cited
US3598122A
Cited
US3797494A
Cited
US3598122B1
Cited
US3903256A
Cited
US3896238A
Cited
US3952099A
Cited
US4046886A
Cited
US4144317A
Cited
US4405616A
Cited
US4031894A
Cited
US4130667A
Cited
US4130643A
Cited
US4335115A
Cited
US4299826A
Cited
US4286592A
Cited
US4314557A
Cited
US4379454A
Cited
US4343798A
Cited
US4568343A
Cited
US4764379A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1992-04-10 | 1992-10-10 | 1993-04-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1996-04-10 | 1996-10-10 | 1997-04-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2000-04-10 | 2000-10-10 | 2001-04-11 | $7700.00 | Window Closed / Lapsed |